S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
AI Creates New Cancer Drug - In Just 30 Days! (Ad)
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
PwC Australia sidelines 9 directors as leak of tax information investigated
[BREAKING] Small Firm Develops World's First Anti-Aircraft Laser (Ad)
North Korea notifies neighboring Japan it plans to launch satellite in coming days
Drought-struck Barcelona quenches thirst with costly desalination
Free A.I. Trade Alerts. Up to 15 opportunities a day. (Ad)
Takeaways on debt ceiling: McCarthy's balancing act, Biden's choice and the challenges ahead
Debt ceiling agreement gets thumbs up from business groups, jeers from some on political right
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
AI Creates New Cancer Drug - In Just 30 Days! (Ad)
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
PwC Australia sidelines 9 directors as leak of tax information investigated
[BREAKING] Small Firm Develops World's First Anti-Aircraft Laser (Ad)
North Korea notifies neighboring Japan it plans to launch satellite in coming days
Drought-struck Barcelona quenches thirst with costly desalination
Free A.I. Trade Alerts. Up to 15 opportunities a day. (Ad)
Takeaways on debt ceiling: McCarthy's balancing act, Biden's choice and the challenges ahead
Debt ceiling agreement gets thumbs up from business groups, jeers from some on political right
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
AI Creates New Cancer Drug - In Just 30 Days! (Ad)
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
PwC Australia sidelines 9 directors as leak of tax information investigated
[BREAKING] Small Firm Develops World's First Anti-Aircraft Laser (Ad)
North Korea notifies neighboring Japan it plans to launch satellite in coming days
Drought-struck Barcelona quenches thirst with costly desalination
Free A.I. Trade Alerts. Up to 15 opportunities a day. (Ad)
Takeaways on debt ceiling: McCarthy's balancing act, Biden's choice and the challenges ahead
Debt ceiling agreement gets thumbs up from business groups, jeers from some on political right
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
AI Creates New Cancer Drug - In Just 30 Days! (Ad)
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
PwC Australia sidelines 9 directors as leak of tax information investigated
[BREAKING] Small Firm Develops World's First Anti-Aircraft Laser (Ad)
North Korea notifies neighboring Japan it plans to launch satellite in coming days
Drought-struck Barcelona quenches thirst with costly desalination
Free A.I. Trade Alerts. Up to 15 opportunities a day. (Ad)
Takeaways on debt ceiling: McCarthy's balancing act, Biden's choice and the challenges ahead
Debt ceiling agreement gets thumbs up from business groups, jeers from some on political right
NASDAQ:CDNA

CareDx (CDNA) Price Target & Analyst Ratings

$7.96
-0.13 (-1.61%)
(As of 05/26/2023 08:46 PM ET)
Compare
Today's Range
$7.91
$8.22
50-Day Range
$7.61
$9.46
52-Week Range
$6.22
$27.35
Volume
521,800 shs
Average Volume
1.18 million shs
Market Capitalization
$428.17 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$16.00

CareDx Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Hold
Based on 5 Analyst Ratings

Consensus Analyst Price Target

$16.00
101.01% Upside
High Prediction$25.00
Average Prediction$16.00
Low Prediction$9.00
TypeCurrent
5/29/22 to 5/29/23
1 Month Ago
4/29/22 to 4/29/23
3 Months Ago
2/28/22 to 2/28/23
1 Year Ago
5/29/21 to 5/29/22
Consensus Rating
Hold
Hold
Buy
Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
Buy
1 Buy rating(s)
2 Buy rating(s)
4 Buy rating(s)
4 Buy rating(s)
Hold
4 Hold rating(s)
3 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$16.00$16.00$23.80$76.50
Predicted Upside101.01% Upside33.98% Upside50.98% Upside39.49% Upside
Get CareDx Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for CDNA and its competitors with MarketBeat's FREE daily newsletter.


CDNA Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

CDNA Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

CareDx Stock vs. The Competition

TypeCareDxMedical CompaniesS&P 500
Consensus Rating Score
2.20
2.66
2.49
Consensus RatingHoldBuyHold
Predicted Upside101.01% Upside1,396.20% Upside186.85% Upside
News Sentiment RatingPositive News
Positive News
Positive News

Historical Target Prices and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
5/11/2023BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Neutral
3/7/2023The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy$25.00 ➝ $13.00+22.53%
3/7/2023Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOverweight ➝ Equal Weight$19.00 ➝ $9.00-15.49%
3/3/2023Craig Hallum
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold$26.00 ➝ $9.00-16.40%
3/3/2023Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeStrong-Buy ➝ Market Perform$24.00+122.94%
(Data available from 5/29/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)












CDNA Price Target - Frequently Asked Questions

What is CareDx's consensus rating and price target?

According to the issued ratings of 5 analysts in the last year, the consensus rating for CareDx stock is Hold based on the current 4 hold ratings and 1 buy rating for CDNA. The average twelve-month price prediction for CareDx is $16.00 with a high price target of $25.00 and a low price target of $9.00. Learn more on CDNA's analyst rating history.

Do Wall Street analysts like CareDx more than its competitors?

Analysts like CareDx less than other Medical companies. The consensus rating for CareDx is Hold while the average consensus rating for medical companies is Buy. Learn more on how CDNA compares to other companies.

Is CareDx being downgraded by Wall Street analysts?

Over the previous 90 days, CareDx's stock had 4 downgrades by analysts.

Does CareDx's stock price have much upside?

According to analysts, CareDx's stock has a predicted upside of 40.49% based on their 12-month price targets.

What analysts cover CareDx?

CareDx has been rated by BTIG Research, Craig Hallum, Raymond James, Stephens, and The Goldman Sachs Group in the past 90 days.


Stock Ratings Reports and Tools

This page (NASDAQ:CDNA) was last updated on 5/29/2023 by MarketBeat.com Staff

My Account -